News

Digital calculator provides the estimated risk for GIST recurrence

The calculator is based on a risk analysis model published in 2012 by Aalto University and HUCH Cancer Center.
GIST Risk calculator significantly improves the process of evaluating the risk of GIST (Gastrointestinal Stromal Tumor) recurrence and the need for additional treatment after surgery.

GIST (Gastrointestinal Stromal Tumour) is an uncommon type of sarcoma found in the tissues supporting the digestive system (stomach and intestines). Approximately one percent of all gastrointestinal cancers are GISTs. The digital calculator predicts the risk for GIST recurrence based on tumour size, mitotic count, tumour site and rupture.

The GIST Risk calculator is based on research conducted by Professor Heikki Joensuu and his co-workers where an international sample of 2000 diagnosed GIST patients were analyzed with the help of a mathematical model designed by Professor Aki Vehtari of Aalto University.

“The nonlinear mathematic model predicts the combined effect of the main prognostic factors more accurately than any known model before. However, it is important to note that the historical data is solely comprised of patients that were treated via surgery only, and that new targeted therapy drugs have reduced the risk of recurrence. The prognostic contour maps resulting from non-linear modelling have been widely accepted by doctors, but digital calculator significantly improves the usability of the maps”, informs Aki Vehtari, Professor at the Aalto University Department of Computer Science.

Uniquely large sample and accurate modelling

“Providing the patient with a reliable estimation of recurrence is faster with the digital calculator. Expensive drugs that can also have side-effects can thus be targeted to the high-risk patients who are not likely to be cured by surgery alone. The risk estimation should be examined together with the patient in order to guarantee that the patient understands the reasons behind treatment decisions”, explains Heikki Joensuu, Professor of Oncology at the University of Helsinki, and the Research Director at the Helsinki Comprehensive Cancer Centre.

”GIST Risk calculator is a great example of how preventive cancer care can be further developed by using modern technology to analyze health data, and proof of the improved results that can be achieved through cooperation of startups, hospitals and universities”, states Lauri Sippola, CEO of Netmedi.

The GIST Risk Calculator is accessible online for all cancer care and research professionals.

More information:

Aki Vehtari, professor, Aalto University
+358 40 5333 747
[email protected]

Paavo Holi, HUCH communications
+358 50 427 9517
[email protected]

Lauri Sippola, CEO, Netmedi Oy
+358 40 7447 481
[email protected]

  • Published:
  • Updated:
Share
URL copied!

Related news

KTT Sami Itani
Research & Art Published:

Doctor’s career path: CEO Sami Itani’s story

‘Doctoral studies consist of team-based project work in which you can act as your own project manager.’
kaksi naista istuu punaisilla tuoleilla studiossa keskustelemassa, taustalla musta verho ja keltainen lattia
Research & Art, Studies Published:

What can we learn from the pandemic?

Aalto University's studio discussion focused on what the COVID-19 pandemic has taught us about the importance of the environment for health and wellbeing.
Assistant Professor Peter Nyberg, McKinsey Teacher of the Year 2020.
Honoured, Research & Art Published:

Aalto BIZ Teacher of the Year 2020

Finance Assistant Professor Peter Nyberg has been nominated as the Aalto BIZ Teacher of the Year 2020.
Machine Learning Coffee Seminar logo in purple and white colours
Research & Art Published:

Machine Learning Coffee Seminars continue with a great lineup of speakers

MLCS gathers together people from different fields of science who have at least one thing in common, interest in machine learning